NASDAQ:EPRX Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis $2.54 +0.06 (+2.42%) (As of 09/6/2024 08:48 PM ET) Add Compare Share Share Today's Range$2.44▼$2.6050-Day Range$2.40▼$2.8652-Week Range$2.39▼$5.58Volume6,400 shsAverage Volume16,751 shsMarket Capitalization$69.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Eupraxia Pharmaceuticals alerts: Email Address Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> About Eupraxia Pharmaceuticals Stock (NASDAQ:EPRX)Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Read More EPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPRX Stock News HeadlinesSeptember 4, 2024 | prnewswire.comEupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 8, 2024 | finanznachrichten.deEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial ResultsSeptember 9, 2024 | Stansberry Research (Ad)Wall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.August 7, 2024 | prnewswire.comEupraxia Pharmaceuticals Reports Second Quarter 2024 Financial ResultsAugust 4, 2024 | uk.investing.comEupraxia Pharmaceuticals files report with SECAugust 2, 2024 | prnewswire.comEupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt FacilityJuly 25, 2024 | theglobeandmail.comClosing Bell: Eupraxia Pharmaceuticals Inc up on Wednesday (EPRX)July 20, 2024 | theglobeandmail.comClosing Bell: Eupraxia Pharmaceuticals Inc up on Friday (EPRX)September 9, 2024 | Stansberry Research (Ad)Wall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.July 20, 2024 | theglobeandmail.comClosing Bell: Eupraxia Pharmaceuticals Inc down on Thursday (EPRX)July 8, 2024 | prnewswire.comEupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and ExpoJuly 3, 2024 | prnewswire.comEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024June 6, 2024 | prnewswire.comEupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersJune 5, 2024 | prnewswire.comEupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024May 23, 2024 | prnewswire.comEupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisMay 22, 2024 | prnewswire.comEupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024May 21, 2024 | prnewswire.comEupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisMay 14, 2024 | prnewswire.comEupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024See More Headlines Receive EPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/08/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EPRX Previous SymbolNASDAQ:EPRX CUSIPN/A CIK1581178 Webwww.eupraxiapharma.com Phone250-590-3968FaxN/AEmployees29Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-208.37% Return on Assets-82.29% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.49 per share Price / Book5.18Miscellaneous Outstanding Shares27,282,000Free FloatN/AMarket Cap$69.30 million OptionableN/A BetaN/A 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key CompetitorsHeron TherapeuticsNASDAQ:HRTXAdaptimmune TherapeuticsNASDAQ:ADAPPoseida TherapeuticsNASDAQ:PSTXuniQureNASDAQ:QUREDesign TherapeuticsNASDAQ:DSGNView All CompetitorsInstitutional Ownership180 Wealth Advisors LLCBought 13,000 shares on 7/17/2024Ownership: 0.048%View All Institutional Transactions EPRX Stock Analysis - Frequently Asked Questions How have EPRX shares performed this year? Eupraxia Pharmaceuticals' stock was trading at $2.72 at the beginning of the year. Since then, EPRX stock has decreased by 6.6% and is now trading at $2.54. View the best growth stocks for 2024 here. How were Eupraxia Pharmaceuticals' earnings last quarter? Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) posted its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.17) earnings per share for the quarter. Who are Eupraxia Pharmaceuticals' major shareholders? Top institutional investors of Eupraxia Pharmaceuticals include 180 Wealth Advisors LLC (0.05%). How do I buy shares of Eupraxia Pharmaceuticals? Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EPRX) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredWall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
